Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Among the genes implicated for parkinsonism is glucocerebrosidase (GBA), which causes Gaucher disease (GD). Despite a growing literature that GD may present as parkinsonism, neuroimaging, olfaction, and neuropsychological testing have not been extensively reported. We describe transcranial sonography (TCS), 18F‐fluorodopa (F‐dopa) and fluorodeoxyglucose (FDG) Positron emission tomography, olfaction testing, neuropsychological testing, and clinical features in homozygous and compound heterozygous GBA mutation carriers identified through screening of 250 Ashkenazi Jewish parkinsonian individuals treated at a tertiary care center. We identified two individuals with N370S/R496H compound heterozygous mutations and two with N370S homozygous mutations; one individual died before completing detailed evaluation. TCS (n = 3) demonstrated nigral hyperechogenicity that was greater than controls [median area maximal substantia nigra echogenicity (aSNmax) = 0.28 cm 2 vs. 0.14 cm 2, P = 0.005], but similar to idiopathic PD (aSNmax = 0.31 cm 2). FDG PET (n = 2) demonstrated hypermetabolism of the lentiform nuclei, and F‐fluorodopa PET (n = 2), bilateral reduction in striatal F‐dopa uptake. Olfaction was markedly impaired in the two tested cases, including onset of smell disturbance in adolescence in one. Neuropsychological features (n = 3) were consistent with Parkinson's disease (PD) or diffuse Lewy body disease (DLB). The imaging, neuropsychological and olfactory markers suggest the GD phenotype includes PD with and without features of DLB, marked olfactory loss, nigral hyperechogenicity on TCS, and F‐dopa and FDG PET abnormalities. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doty, R. L., Shaman, P., & Dann, M. (1984) · Physiology & Behavior · doi:10.1016/0031-9384(84)90269-5 · Cited by 1,854
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597 · cited 1×
“Most reported cases of PD associated with GD are ascertained because of systemic features, such as anemia or bone changes; only a few cases of GBA homozygotes or compound heterozygotes, asymptomatic for other features of GD, have been identified in a PD clinic setting.(2,14) Further, neuroimaging, and formal neuropsyc…”
BackgroundZecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214
Cited by
Olfactory dysfunction in Parkinson disease
Doty, R. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.80 · Cited by 737
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431
Olfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
“Finally, individuals with heterozygous GBA mutations (Doty, 2012b; Goker-Alpan et al., 2008; Saunders-Pullman et al., 2010), who have a six-fold greater risk of PD (Setó-Salvia et al.”
Aflaki, E., Borger, D. K., Moaven, N., Stubblefield, B. K., Rogers, S. A., Patnaik, S., Schoenen, F. J., Westbroek, W., Zheng, W., Sullivan, P., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0636-16.2016 · Cited by 227
“His brother (GD1–1), also with genotype N370S/N370S, and now 64 years old, has GD but no manifestations of PD. Patient GD1-PD2 with genotype N370S/c.84dupG developed parkinsonian manifestations at age 45 and died at age 59 with a postmortem diagnosis of DLB. Differentiation of iPSCs to monocytes and macrophages.”
BackgroundInfluentialEvolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation–Positive Cohort
Beavan, M., McNeill, A., Proukakis, C., Hughes, D. A., Mehta, A., & Schapira, A. H. V. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2950 · Cited by 205
Chemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Metadata
- Authors
- Saunders‐Pullman, R., Hagenah, J., Dhawan, V., Stanley, K., Pastores, G., Sathe, S., Tagliati, M., Condefer, K., Palmese, C., Brüggemann, N., Klein, C., Roe, A., Kornreich, R., Ozelius, L., & Bressman, S.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-07-23
- Volume
- 25
- Issue
- 10
- Pages
- 1364-1372
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2066498624
- Cited by
- 86
- References
- 4
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.